Hoth Therapeutics Files 8-K: Material Agreement & Financial Restatement

TL;DR

Hoth Therapeutics 8-K: New deal signed, but past financials are unreliable. Big changes ahead.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on March 25, 2025, reporting a material definitive agreement and a non-reliance on previously issued financial statements. The filing date for the report is March 21, 2025.

Why It Matters

This filing indicates potential issues with past financial reporting and the execution of a significant new agreement, which could impact investor confidence and future operations.

Risk Assessment

Risk Level: medium — The non-reliance on previously issued financial statements suggests potential accounting irregularities or restatements, which introduces uncertainty.

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — Registrant
• March 21, 2025 (date) — Date of earliest event reported
• March 25, 2025 (date) — Filing date
• 1177 Avenue of the Americas, 5th Floor, Suite 5066 New York, NY 10036 (address) — Principal executive offices

FAQ

From the Filing

0001013762-25-002271.txt : 20250325 0001013762-25-002271.hdr.sgml : 20250325 20250325172507 ACCESSION NUMBER: 0001013762-25-002271 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250321 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250325 DATE AS OF CHANGE: 20250325 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 25769411 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 8-K 1 ea0235633-8k_hoth.htm CURRENT REPORT false 0001711786 0001711786 2025-03-21 2025-03-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) March 21, 2025   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   1177 Avenue of the Americas , 5th Floor , Suite 5066 New York , NY 10036 (Address of principal executive offices, including ZIP code)   ( 646 ) 756-2997 (Registrant’s telephone number, including area code)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐               Item 1.01 Entry into a Material Definitive Agreement.   On March 24, 2024, Hoth Therapeutics, Inc. (“Hoth” or the “Company”) entered into a Project Order Agreement (the “Agreement”) with OnTargetx R&D Inc. (“OnTargetx”) pursuant to the terms of an existing Master Service Agreement originally enter